ISSN 1674-3865  CN 21-1569/R
主管:国家卫生健康委员会
主办:中国医师协会
   辽宁省基础医学研究所
   辽宁中医药大学附属医院

中国中西医结合儿科学 ›› 2017, Vol. 9 ›› Issue (5): 401-403.doi: 10.3969/j.issn.1674-3865.2017.05.011

• 临床研究 • 上一篇    下一篇

匹多莫德口服液治疗支气管哮喘患儿疗效观察

张改玲,余秀红,漆筱萍,冯斌   

  1. 518000 广东 深圳,深圳市南山区人民医院儿科
  • 出版日期:2017-10-25 发布日期:2017-12-18
  • 通讯作者: 张改玲,E-mail:zhanggailing01@126.com

Clinical observation on the effect of pidotimod oral liquid on children with bronchial asthma

ZHANG Gailing,YU Xiuhong,QI Xiaoping,FENG Bin   

  1. Department of Pediatrics, Nanshan District People's Hospital of Shenzhen,Shenzhen 518000,China
  • Online:2017-10-25 Published:2017-12-18

摘要:
目的
观察匹多莫德口服液对支气管哮喘患儿临床疗效。
方法
选取2014年8月至2016年8月深圳市南山区人民医院儿科收治住院的哮喘患儿120例为研究对象,随机分为观察组和对照组各60例。对照组患儿给予吸氧、止咳、祛痰、解痉、平喘、抗感染等常规对症治疗,观察组患儿在对照组治疗基础上加用匹多莫德口服液治疗,4周为1个疗程,共治疗3个疗程。观察患儿临床症状、体征变化及肺功能(第1秒用力呼气容积、用力肺活量、最大呼气流量)、免疫功能的改善和疗效情况。
结果
观察组总有效率为93.3%(56/60),显著高于对照组73.3%(44/60),差异有统计学意义(P<0.05)。观察组治疗后第1秒用力呼气容积、用力肺活量、最大呼气流量显著高于对照组,差异有统计学意义(P<0.05)。观察组治疗后CD3+、CD4+水平和CD4+/CD8+比值显著高于对照组,CD8+显著低于对照组,差异有统计学意义(P<0.05)。
结论
匹多莫德口服液治疗小儿支气管哮喘疗效显著,安全性较好,能够明显提高患儿免疫力,临床推广、应用价值更高。

关键词: 哮喘, 匹多莫德, 免疫功能, 儿童

Abstract:
Objective
To observe the clinical effect of pidotimod oral liquid on children with bronchial asthma.
Methods
A total of 120 children with asthma were included as the research subjects, and were randomly divided into two groups: the observation group(60 cases) and the control group(60 cases). The children in both groups were given conventional expectant treatment of oxygen inhalation, relieving cough, eliminating phlegm, and spasmolytic, antiasthmatic and anti-infection therapy; the children in observation group was also treated with pidotimod oral liquid, four weeks as a course for 3 courses. Observe the clinical symptoms, changes in symptoms and lung function, immune function and the clinical effect.
Results
The total effective rate of observation group was 93.3%(56/60) significantly higher than that of control group(73.3%,44/60),the difference being statistical(P<0.05).After treatment,FEV1, FVC and maximal expiratory flow of observation group were significantly higher than those of control group, and there was statistical difference(P<0.05).The level of CD3+ and CD4+ and CD4+/CD8+ ratio were significantly higher in observation group than in control group after treatment, while CD8+ level was significantly lower, the difference being statistical(P<0.05).
Conclusion
Pidotimod oral liquid has significant effect in treating children with bronchial asthma; it is safe and can significantly improve the children's immunity, which is worthy of clinical promotion.

Key words: Asthma, Pidotimod, Immunologic function, Children